Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
Regulatory Filings Classification · 95% confidence The document is a Form 6-K submission by a foreign private issuer to the U.S. SEC, containing the company’s press release, interim condensed financial statements, and operating and financial review. It is a regulatory filing under the Securities Exchange Act of 1934 rather than a standalone annual report, management discussion, earnings release, or investor presentation. Under our taxonomy, Form 6-K and similar SEC compliance submissions are classified as ‘Regulatory Filings’ (RNS).
2026-05-27 English
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
Report Publication Announcement Classification · 88% confidence The document is a brief immediate report under Israeli and NASDAQ regulations, merely stating that the Form 6-K containing the Q1 2026 financial results is attached. It provides no substantive financial data itself but announces the publication of the Form 6-K report. Per the “menu vs. meal” rule for short announcements stating a report is attached, this is a Report Publication Announcement.
2026-05-27 English
6-K
Regulatory Filings
2026-05-27 English
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Regulatory Filings Classification · 91% confidence The document is a Form 6-K submitted to the SEC by a foreign private issuer (BioLineRx Ltd.) attaching a press release about clinical data announcements. It does not contain actual financial statements or management analysis, nor is it an AGM, earnings release, or share transaction. As an SEC compliance filing that reports a press release, it falls into the general “Regulatory Filings” category (RNS).
2026-05-24 English
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Report Publication Announcement Classification · 87% confidence The document is a short Immediate Report under Israeli securities regulations, stating that a Form 6-K report is attached (Form_6-K_24-May-26_isa.pdf) without including substantive content itself. Per the “menu vs meal” rule, it merely announces the publication of the report, so it should be classified as a Report Publication Announcement (RPA).
2026-05-24 English
6-K
Regulatory Filings
2026-05-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.